# Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

> **NCT00548405** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 840 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **BIOLOGICAL:** Alemtuzumab 12 mg
- **BIOLOGICAL:** Alemtuzumab 24 mg
- **BIOLOGICAL:** Interferon beta-1a

## Key facts

- **NCT ID:** NCT00548405
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 840 (ACTUAL)
- **Last updated:** 2017-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00548405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00548405, "Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00548405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*